BioLife Solutions, Inc. revised earnings guidance for the full year 2023. For the period, the company expects revenue at the low end of the previously announced guidance range of $144 million to $158 million, which assumes flat to modest sequential growth for its cell processing platform in the fourth quarter.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.16 USD | +3.89% | +7.71% | +11.75% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.75% | 792M | |
-3.77% | 184B | |
-1.77% | 107B | |
-1.43% | 67.52B | |
+2.06% | 50.06B | |
+9.43% | 45.67B | |
+3.40% | 41B | |
+3.04% | 26.73B | |
+4.64% | 26.47B | |
+15.23% | 25.05B |
- Stock Market
- Equities
- BLFS Stock
- News BioLife Solutions, Inc.
- BioLife Solutions, Inc. Revises Earnings Guidance for the Full Year 2023